Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
Immuneering Corporation is holding a virtual 2026 annual stockholder meeting on June 11, 2026 at 11:00 a.m. Eastern Time. Stockholders will vote on electing two Class II directors, Peter Feinberg and Laurie B. Keating, to terms running to the 2029 annual meeting, and on ratifying RSM US LLP as independent registered public accounting firm for the year ending December 31, 2026. Holders of 64,697,227 outstanding shares of Class A common stock as of April 15, 2026 are entitled to one vote per share and may vote by internet, telephone, mail, or during the live webcast.
Immuneering Corp’s Chief People Officer, Leah R. Neufeld, acquired additional company stock through an employee plan. She obtained 3,628 shares of Class A Common Stock on the ESPP Purchase Date of March 13, 2026 at $4.2925 per share, under the 2021 Employee Stock Purchase Plan for the offering period from September 16, 2025 through March 15, 2026. The plan price was set at not less than 85% of the fair market value on the purchase date. Following this routine, compensation-related acquisition, Neufeld directly holds 29,598 shares, and the transaction is exempt under Rule 16b-3(c).
Immuneering Corporation is a late-stage clinical oncology company developing Deep Cyclic Inhibitors, a new class of targeted cancer drugs designed to intermittently block tumor signaling while sparing healthy cells.
Lead candidate atebimetinib (IMM-1-104), an oral MEK inhibitor, is moving toward a global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic ductal adenocarcinoma, with about 510 patients planned and first dosing expected in mid-2026. Positive Phase 1/2a data in pancreatic cancer showed encouraging survival and tolerability, and the drug holds FDA Fast Track and orphan designations for pancreatic cancer and Fast Track for NRAS-mutant melanoma.
Second program envometinib (IMM-6-415) showed promising early PK/PD and safety but has been paused internally while partnership options are explored.
For 2025, Immuneering reported a net loss of $56.0M on operating expenses of $59.4M, mainly R&D. Significant 2025 equity offerings lifted cash, cash equivalents and marketable securities to $217.0M, which management believes can fund operations into 2029.
Immuneering Corporation reported fourth-quarter and full-year 2025 results alongside major clinical progress for its lead cancer drug candidate, atebimetinib. In an ongoing Phase 2a trial in first-line pancreatic cancer, atebimetinib plus mGnP showed 64% overall survival at 12 months, compared with a 35% standard-of-care benchmark for GnP.
The company finished 2025 with $217 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Fourth-quarter 2025 research and development expenses fell to $9.3 million from $14.9 million a year earlier, while general and administrative expenses rose to $4.5 million. Net loss narrowed to $11.6 million, or $0.18 per share, from $18.1 million, or $0.58 per share.
Immuneering plans to start dosing in its pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer in mid-2026 and initiate a Phase 2 lung cancer trial of atebimetinib plus Libtayo in the second half of 2026.
Immuneering Corp’s chief legal officer and secretary, Michael Bookman, received a new stock option grant. On February 3, 2026, he was awarded options to purchase 176,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026, and will be fully vested and exercisable on January 1, 2030. All 176,000 derivative securities are reported as directly owned following this grant.
Immuneering Corp reported that its Chief Business Officer, Harold Eugene Brakewood, received a stock option award covering 140,000 shares of Class A common stock on February 3, 2026. The option has an exercise price of $4.91 per share and is held directly.
The option vests in equal monthly installments over four years, beginning on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. After this grant, Brakewood beneficially owns 140,000 derivative securities linked to Immuneering’s Class A common stock.
Immuneering Corp's chief scientific officer, Brett Matthew Hall, reported a new stock option grant. On February 3, 2026, he was awarded options to purchase 344,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years, starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. After this grant, Hall beneficially owns 344,000 stock options, all held directly.
Immuneering Corp’s Chief Medical Officer, Igor Matushansky, received a new stock option grant. On February 3, 2026, he was awarded options to acquire 140,000 shares of Class A common stock at an exercise price of $4.91 per share.
The options vest in equal monthly installments over four years starting February 1, 2026 and are scheduled to be fully vested and exercisable on January 1, 2030, aligning long-term compensation with the company’s future performance.
Immuneering Corp executive Mallory Morales, SVP Finance and Chief Accounting Officer, received a grant of stock options covering 140,000 shares of Class A common stock on February 3, 2026. The options have an exercise price of $4.91 per share and were granted at no cost.
The option award vests in equal monthly installments over four years starting February 1, 2026 and will be fully vested and exercisable on January 1, 2030. Following this grant, Morales beneficially owns 140,000 stock options directly.
Immuneering Corp’s chief people officer receives new stock options grant. Leah R. Neufeld was awarded stock options covering 140,000 shares of Class A common stock on February 3, 2026, with an exercise price of $4.91 per share and no purchase price for the options themselves.
The options vest in equal monthly installments over four years starting February 1, 2026, and are scheduled to be fully vested and exercisable on January 1, 2030. Following this grant, Neufeld beneficially owns 140,000 derivative securities directly through this option award.